Polymer-based nanocarriers to transport therapeutic biomacromolecules across the blood-brain barrier DOI Creative Commons
Elena Romero‐Ben, Upashi Goswami, Javier Cruz

et al.

Acta Biomaterialia, Journal Year: 2025, Volume and Issue: unknown

Published: March 1, 2025

Therapeutic biomacromolecules such as genetic material, antibodies, growth factors and enzymes represent a novel therapeutic alternative for neurological diseases disorders. In comparison to traditional therapeutics, which are mainly based on small molecular weight drugs that address the symptoms of these disorders, can reduce undesired side effects target specific pathological pathways, thus paving way towards personalized medicine. However, undergo degradation/denaturation processes in physiological environment show poor capacity cross blood-brain barrier (BBB). Consequently, they rarely reach central nervous system (CNS) their active form. Herein, we critically overview several polymeric nanocarriers protect deliver across BBB. Polymeric first categorized architecture (biodegradable solid nanoparticles, nanogels, dendrimers, self-assembled nanoparticles), ultimately determines physico-chemical properties function. The available formulations then thoroughly analyzed, placing particular attention those strategies ensure stability during encapsulation process promote passage BBB by controlling physical (e.g., mechanical properties, size, surface charge) chemical functional groups, targeting motifs) properties. Accordingly, this review gives unique perspective delivery BBB, representing concise, complete easy-to-follow guide, will be high interest chemists, material scientists, pharmacologists biologists. Besides, it also provides critical about limited clinical translation systems. STATEMENT OF SIGNIFICANCE: increasing incidence disorders is major health concern. use has been placed spotlight many investigations. reaching concentration levels restricted and, thus, represents main challenge when developing efficient therapies. provide discussion into system, highlighting potential future directions overcome current challenges.

Language: Английский

Polymer-based nanocarriers to transport therapeutic biomacromolecules across the blood-brain barrier DOI Creative Commons
Elena Romero‐Ben, Upashi Goswami, Javier Cruz

et al.

Acta Biomaterialia, Journal Year: 2025, Volume and Issue: unknown

Published: March 1, 2025

Therapeutic biomacromolecules such as genetic material, antibodies, growth factors and enzymes represent a novel therapeutic alternative for neurological diseases disorders. In comparison to traditional therapeutics, which are mainly based on small molecular weight drugs that address the symptoms of these disorders, can reduce undesired side effects target specific pathological pathways, thus paving way towards personalized medicine. However, undergo degradation/denaturation processes in physiological environment show poor capacity cross blood-brain barrier (BBB). Consequently, they rarely reach central nervous system (CNS) their active form. Herein, we critically overview several polymeric nanocarriers protect deliver across BBB. Polymeric first categorized architecture (biodegradable solid nanoparticles, nanogels, dendrimers, self-assembled nanoparticles), ultimately determines physico-chemical properties function. The available formulations then thoroughly analyzed, placing particular attention those strategies ensure stability during encapsulation process promote passage BBB by controlling physical (e.g., mechanical properties, size, surface charge) chemical functional groups, targeting motifs) properties. Accordingly, this review gives unique perspective delivery BBB, representing concise, complete easy-to-follow guide, will be high interest chemists, material scientists, pharmacologists biologists. Besides, it also provides critical about limited clinical translation systems. STATEMENT OF SIGNIFICANCE: increasing incidence disorders is major health concern. use has been placed spotlight many investigations. reaching concentration levels restricted and, thus, represents main challenge when developing efficient therapies. provide discussion into system, highlighting potential future directions overcome current challenges.

Language: Английский

Citations

0